Table 1 Baseline characteristics of patients (N = 247)
Variables | n (%), mean ± SD, or median (range) |
|---|---|
Age (years) | 53.3 ± 10.3 |
Gender (Male /Female) | 213/34(86%/14%) |
BMI (kg /m2) | 29.9 ± 16.5 |
Complicationsa | 43(17%) |
Cirrhosis (yes /no) | 76/171(30.8%/69.2%) |
White blood cell (109/l) | 5.2 ± 2.0 |
Hemoglobin (g/l) | 143.9 ± 14.1 |
Platelet Count (109/l) | 145(41–466) |
Child–Pugh class A | 247 |
Total bilirubin (umol/l) | 16.0 ± 11.8 |
Albumin (g/l) | 41.7 ± 3.3 |
Prealbumin (mg/l) | 238.6 ± 62.6 |
Alanine transaminase (u/l) | 39.2 ± 34.2 |
Aspartate aminotransferase (u/l) | 36.99 ± 31.3 |
Gamma-glutamyl transpeptidase (u/l) | 47(11–866) |
Alkaline phosphatase (u/l) | 81(34–250) |
PT(s) | 11.5(9.4–15.4) |
INR | 1.0(0.8–1.3)- |
APTT(s) | 27.2(16.7–52.9) |
LSM(Kpa) | 12.7(3.8–38.5) |
Intraoperative blood infusion (yes / no) | 19/228(8%/92%) |
Portal vein occlusion (yes / no) | 194/53(79%/21%) |
Esophageal varices (yes / no) | 18/229(7.3%/92.7%) |
Tumor capsule (yes / no) | 174/73(70%/30%) |
Number of tumors (Single / multiple) | 217/30(88%/12%) |
Anti-viral medication(Positive / negative) | 71/176(28.7%/71.2%) |
HBV DNA levels (>1.0E + 04iu/ml/<1.0E + 04iu/ml) | 73/174(30%/70%) |
Major hepatectomy | 40 (16%) |
Median main tumor size(cm) | 5.02 ± 3.18 |
Tumor location (right lobe /left lobe/ both) | 158/79/10(64%/32%/4%) |